

**Supplementary Table S1.** Losses to follow-up at 2.5 years of follow-up.

	Total	RA	AS	PsA	Controls
Active, n (%)	2588 (88.9)	704 (91.2)	656 (89.2)	659 (91.8)	569 (84.5)
Withdrawals, n (%)	105 (3.6)	14 (1.8)	20 (2.7)	19 (2.6)	52 (7.7)
Lost to follow-up in the follow-up, n (%)	63 (2.2)	16 (2.1)	15 (2.0)	13 (1.8)	19 (2.8)
Without follow-up, n (%)	114 (3.9)	26 (3.4)	37 (5.0)	21 (2.9)	30 (4.4)
Other causes, n (%)	4 (0.1)	1 (0.1)	1 (0.1)	1 (0.1)	1 (0.1)

N: number; CV: cardiovascular; RA: rheumatoid arthritis; AS: ankylosing spondylitis; PsA: psoriatic arthritis. Withdrawals: patients who left the study voluntarily.

**Supplementary Table S2.** Main features in individuals who were lost in follow-up vs. those who were evaluated at 2.5 years of follow-up.

Variables	Individuals lost to follow-up (n=316)	Individuals who were seen at the 2.5 years follow-up visit (n=2595)	p-value
Age at the onset of the study (years), mean (SD)	51.4 (13.9)	52.4 (12.4)	0.27
Sex (woman), (%)	54.6	52.9	0.56
Educational level, (%)			
Elementary	71	75.7	0.83
Secondary	27.2	27.1	
University	26.8	26.3	
Diabetes mellitus, (%)	2.2	1.7	0.52
History of IHD prior to basal visit, (%)	8.9	7.9	0.50
Family history of CV disease, (%)	12.1	12.7	0.77
Hypercholesterolaemia, (%)	28.3	31.9	0.14
Hypertension, (%)	33	26.7	0.03
Smoking status, (%)			
Current smokers	30.8	24.9	<0.03
Past smokers	23.2	29.7	
Never smoking	46	45.4	
SCORE at the basal visit, (%)			
Low	55.3	51.3	<0.05
Moderate	28.3	35.8	
High	16.4	12.9	
Disease duration (years), median [p25-p75]	6 [2-14]	9 [3-16]	0.001
DAS28-ESR, mean (SD)	3.2 (1.1)	3.08 (1.3)	0.33
BASDAI, media (SD)	3.5 (2.3)	3.6 (2.2)	0.61
PASI, median [p25-p75]	0.6 [0.0-1.8]	0.6 [0.0-2.1]	0.85
HAQ, median [p25-p75]	0.5 [0.1-1.1]	0.5 [0.0-1.1]	0.46
RF positive, (%)	75	76.8	0.74
ACPA positive, (%)	63.2	59.4	0.54
HLA-B27, (%)	77.5	75.8	0.74
Erosions, (RA), (%)	28.3	26.8	0.79
Sacroiliitis, (%)	51.3	57.6	0.28
ESR (mm/1 <sup>st</sup> h), median [p25-p75]	11 [5.2-21]	12 [6-23]	0.03
CRP (mg/dl), median [p25-p75]	2.9 [1-7.2]	2.9 [1.1-6.5]	0.85

ACPA: anti-cyclic citrullinated peptide antibodies; BASDAI (0-10): Bath Ankylosing Spondylitis (AS) Disease Activity Score; BASFI (0-10): Bath AS Functional Index; BMI: body mass index; CRP: C-reactive protein; CV: cardiovascular; DAS28-ESR: Disease Activity Score using 28 joints-erythrocyte sedimentation rate; HAQ (0-3): Health Assessment Questionnaire; HLA-B27: histocompatibility antigen HLA-B27; IHD: ischaemic heart disease; PASI: Psoriasis Area Score Index; RA: rheumatoid arthritis; RF: rheumatoid factor; SCORE: Systematic Coronary Risk Evaluation model; SD: standard deviation. All variables were collected at the onset of the study.

**Supplementary Table S3.** Effect of the biologic therapy on the incidence of cardiovascular events stratifying each one of the inflammatory arthritis included in our cohort separately.

	Crude HR	95%CI	<i>p</i> -value	Adj. HR	95%CI	<i>p</i> -value
RA	0.49	(0.10-2.43)	0.383	0.35	(0.04-3.10)	0.346
AS	0.52	(0.18-1.53)	0.283	0.67	(0.21-2.10)	0.489
PsA	0.91	(0.26-3.22)	0.885	1.54	(0.31-7.79)	0.595

RA: rheumatoid arthritis; AS: ankylosing spondylitis; PsA: psoriatic arthritis; HR: hazard ratio; CI: confidence interval; Adj.: adjusted.